France
· Delayed Price · Currency is EUR GenSight Biologics Company Description
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system.
The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms.
Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration.
The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases.
It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies.
The company was incorporated in 2012 and is headquartered in Paris, France.
| Country | France |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Laurence Rodriguez |
Contact Details
Address: 74, rue du Faubourg Saint-Antoine Paris, 75012 France | |
| Phone | 33 1 76 21 72 20 |
| Website | gensight-biologics.com |
Stock Details
| Ticker Symbol | SIGHT |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0013183985 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Laurence Rodriguez | Chief Executive Officer and Director |
| Dr. Jose-Alain Sahel M.D., Ph.D. | Scientific Founder, Vice Chairman of Scientific Advisory Board and Board Observer |
| Prof. Botond Roska M.D., Ph.D. | Scientific Founder and Chairman of Scientific Advisory Board |
| Dr. Luk H. Vandenberghe M.D., Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Dr. Serge Picaud Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Dr. Constance L. Cepko Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Jan Eryk Umiastowski | Chief Financial Officer |
| Scott Jeffers | Chief Technical Officer |
| Dr. Barrett Katz CMO, M.B.A., M.D. | Consultant |
| Dr. Magali Taiël M.D. | Chief Medical Officer |